首页> 外文学位 >Mechanisms of highly active antiretroviral therapy (HAART) associated metabolic complications.
【24h】

Mechanisms of highly active antiretroviral therapy (HAART) associated metabolic complications.

机译:高效抗逆转录病毒疗法(HAART)的机制与代谢并发症相关。

获取原文
获取原文并翻译 | 示例

摘要

The introduction of highly active antiretroviral therapy (HAART) has led to a dramatic decrease in viral load and HIV-associated morbidity and mortality, thereby increasing life expectancy among HIV-infected patients. However, long term usage of HAART is linked with metabolic disorders such as lipodystrophy, dyslipidemia, insulin resistance and type II diabetes, thereby increasing the risk of cardiovascular disease (CVD) as well as fetal toxicity due to intrauterine exposure in fetus of HIV-infected mothers on HAART. HAART generally includes a combination of protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse transcriptase inhibitors (NNRTI). Mechanistic studies indicate that PI-associated deregulation of glucose and lipid metabolism may be involved in dyalipidemia and hyperlipidemia, as well as central fat accumulation among HIV-infected patients on HAART, while NRTI-associated mitochondrial toxicity is involved in insulin resistance, diabetes, peripheral lipoatrophy and lactic acidosis in children born to HIV-infected mothers n HAART. The objective of our research was to understand the effects of combination of PI and NRTI on cellular and molecular mechanism involved in: (1) adipocyte differentiation and lipolysis in 3T3-L1 mouse and primary human adipocytes, (2) reverse cholesterol transport in human hepatoma cell line (HepG2) and C57BL/6 mice and (3) adult onset of diseases among offspring with in uteo exposure to HAART. Our data indicates that combination of PI such as ritonavir (RTV), lopinavir (LPV) and NRTI (combivir, CBV), either singly or in combination significantly increased adipocyte differentiation in mouse and human primary adipocytes with a concomitant increase in adipocyte transcription factor regulated genes such as resistin and perilipin. Further studies demonstrate - that CBV and LPV, either single and/or combination increase plasma glucose, lipid and hepatic lipid in C57BL/6 mice. In our studies, regulation of cholesterol metabolism by LPV and CBV were related to differential regulation the nuclear receptors such liver X receptor (LXR), farnesoid X receptor (FXR) in liver and intestine. Administration of CBV and LPV to pregnant mice resulted in increased oxidative stress in offspring up to 9 months of life. In addition, offspring exposed to intrauterine HAART demonstrated impaired glucose tolerance as compared to offspring from control mice. Overall, our data may provide a better understanding of the cellular and molecular mechanisms involved in the pathophysiological processes of HAART-associated toxicities and can help to identify new therapeutic molecular targets to treat these metabolic complications.
机译:高活性抗逆转录病毒疗法(HAART)的引入已导致病毒载量以及与HIV相关的发病率和死亡率急剧下降,从而提高了HIV感染患者的预期寿命。但是,长期使用HAART与代谢异常有关,例如脂肪营养不良,血脂异常,胰岛素抵抗和II型糖尿病,从而增加了心血管疾病(CVD)的风险以及由于感染了HIV的胎儿宫内暴露而引起的胎儿毒性母亲在HAART上。 HAART通常包括蛋白酶抑制剂(PI),核苷逆转录酶抑制剂(NRTI)和非核苷逆转录酶抑制剂(NNRTI)的组合。机理研究表明,PI相关的葡萄糖和脂质代谢失调可能参与了血脂异常和高脂血症,以及在HAART上被HIV感染的患者中的中央脂肪蓄积,而NRTI相关的线粒体毒性涉及胰岛素抵抗,糖尿病,外周血HIV感染母亲所生儿童的脂肪萎缩和乳酸酸中毒。我们的研究目的是了解PI和NRTI组合对涉及以下方面的细胞和分子机制的影响:(1)3T3-L1小鼠和原代人脂肪细胞的脂肪细胞分化和脂解作用;(2)人肝癌中胆固醇的逆向转运细胞株(HepG2)和C57BL / 6小鼠,以及(3)在子宫内暴露于HAART的后代中成年疾病的发作。我们的数据表明,PI的组合(例如利托那韦(RTV),洛匹那韦(LPV)和NRTI(combivir,CBV))单独或组合显着增加了小鼠和人原代脂肪细胞中脂肪细胞的分化,并伴随着脂肪细胞转录因子调节的增加抵抗素和周脂素等基因。进一步的研究表明-CBV和LPV单独和/或组合会增加C57BL / 6小鼠的血浆葡萄糖,脂质和肝脂质。在我们的研究中,LPV和CBV对胆固醇代谢的调节与肝脏和肠中核受体如肝X受体(LXR),法呢类X受体(FXR)的调节有关。对怀孕小鼠施用CBV和LPV会导致后代长达9个月生命的氧化应激增加。另外,与对照小鼠的后代相比,暴露于宫内HAART的后代表现出葡萄糖耐量受损。总体而言,我们的数据可以更好地了解与HAART相关的毒性的病理生理过程有关的细胞和分子机制,并有助于确定新的治疗性分子靶标来治疗这些代谢并发症。

著录项

  • 作者

    Lee, Yun Kyung.;

  • 作者单位

    University of Hawai'i at Manoa.;

  • 授予单位 University of Hawai'i at Manoa.;
  • 学科 Biology Molecular.;Chemistry Biochemistry.;Biology Cell.
  • 学位 Ph.D.
  • 年度 2007
  • 页码 190 p.
  • 总页数 190
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号